<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Influenza virus remains at the forefront of public health research due to the high morbidity and mortality associated with yearly epidemics and sporadic pandemics. Seasonal influenza is estimated to cause up to 79,400 deaths in the US and 291,243 to 645,832 deaths globally
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>–
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup>. Influenza vaccination is the primary method available to mitigate the effect of influenza on the world’s population. Current vaccines rely on specific targeting of the major surface protein, hemagglutinin (HA), and are standardized as stimulating anti-HA antibodies as the primary correlate of protection
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>, but these vaccines have limited and somewhat unpredictable efficacy
 <sup>
  <xref ref-type="bibr" rid="CR7">7</xref>
 </sup>, particularly in those that most require protection such as the elderly, young, and infirm
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup>.
</p>
